Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Boehringer Ingelheim
McKesson
Express Scripts
Johnson and Johnson

Last Updated: August 10, 2022

Valbenazine tosylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for valbenazine tosylate and what is the scope of patent protection?

Valbenazine tosylate is the generic ingredient in one branded drug marketed by Neurocrine and is included in one NDA. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Valbenazine tosylate has one hundred and fifty-eight patent family members in thirty-one countries.

One supplier is listed for this compound.

Pharmacology for valbenazine tosylate
Anatomical Therapeutic Chemical (ATC) Classes for valbenazine tosylate
Paragraph IV (Patent) Challenges for VALBENAZINE TOSYLATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INGREZZA Capsules valbenazine tosylate 60 mg 209241 1 2022-02-14
INGREZZA Capsules valbenazine tosylate 40 mg and 80 mg 209241 4 2021-04-12

US Patents and Regulatory Information for valbenazine tosylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for valbenazine tosylate

Country Patent Number Title Estimated Expiration
Australia 2017395704 Methods for the administration of certain VMAT2 inhibitors See Plans and Pricing
Slovenia 3368534 See Plans and Pricing
Australia 2017395701 Methods for the administration of certain VMAT2 inhibitors See Plans and Pricing
Japan 2019500372 (S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法 See Plans and Pricing
Canada 3002074 SELS DE VALBENAZINE ET POLYMORPHES ASSOCIES (VALBENAZINE SALTS AND POLYMORPHS THEREOF) See Plans and Pricing
Mexico 2019008854 METODOS PARA LA ADMINISTRACION DE CIERTOS INHIBIDORES DEL TRANPORTADOR DE MONOAMINA VESICULAR 2 (VMAT2). (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS.) See Plans and Pricing
Jordan P20200336 طرق إعطاء مثبطات VMAT2 معينة (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Colorcon
AstraZeneca
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.